Statistics from Altmetric.com
The following information has been produced for Veterinary Record by the Veterinary Medicines Directorate (VMD) to provide an update for veterinary surgeons on recent changes to marketing authorisations for veterinary medicines in the UK and other relevant issues.
THE points below highlight changes in marketing authorisations that may have a significant impact on veterinary surgeons' prescribing decisions.
New marketing authorisations
New marketing authorisations issued in July 2011 are listed in Table 1. Of the products authorised in this period, one contains an active ingredient not previously included in an authorised veterinary medicinal product in the UK. This is Vulketan (highlighted in bold blue type in the table), which contains ketanserin.
These products may not yet be readily available in the UK. Veterinary surgeons should contact the marketing authorisation holder directly for details of supply.
Marketing authorisation variations
The following clinically significant variations to marketing authorisations have been approved and/or published during July 2011:
■ Effipro 50 mg spot-on solution for cats.
A new indication for cats has been added as follows:
‘The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) where this has been previously diagnosed by a veterinary surgeon.’
■ Metacam 0.5 mg/ml oral suspension for cats.
The following new therapeutic indication has been included: ‘Alleviation of inflammation and pain in acute and chronic musculoskeletal disorders in cats.’
In addition, the …